"My research focuses on the most lethal type of pediatric brain tumors. I’m exploring whether fast-growing tumor cells can be made to ‘differentiate’ and behave more like normal brain cells. Accomplishing this in the laboratory will be a major step toward the development of new treatments for this disease. Support from the Sontag Foundation is critical in bringing this work to fruition, and I’m proud to be a recipient of the Distinguished Scientist Award."
About DSA-Funded Research
Dr. Filbin's research focuses on establishing cellular networks of tumor dependencies in pediatric brain tumors with the goal of finding new targeted therapies. Current areas of emphasis are: (1) utilizing single-cell transcriptomics to determine the tumor architecture and heterogeneity in pediatric brain tumors and (2) exploring the downstream effects of epigenetic driver mutations and their potential therapeutic applications in DIPG and high-grade gliomas.
Co-Director for Research, Pediatric Neurooncology Program, Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Assistant Professor of Pediatrics, Harvard Medical School
Associate Member, Broad Institute of Harvard and MIT
Medical University of Graz, M.D.
Medical University of Graz, Ph.D., Neuroimmunology
Medical University of Vienna, Residency/Fellowship at Medical University
Dana-Farber Cancer Institute, Postdoctoral Fellowship
Boston Children’s Hospital, Residency, Pediatrics
Dana-Farber Cancer Institute, Fellowship, Pediatric Hematology/Oncology